Inhibition of TNF Receptor p55 By a Domain Antibody Attenuates the Initial Phase of Acid-Induced Lung Injury in Mice

Autor: Wilson, MR, Wakabayashi, K, Bertok, S, Oakley, C, Patel, BV, O'Dea, KP, Cordy, JC, Morley, PJ, Bayliffe, AI, Takata, M

Publikováno v: Frontiers in Immunology. 8

Background: Tumor necrosis factor-α (TNF) is strongly implicated in the development of acute respiratory distress syndrome (ARDS), but its potential as a therapeutic target has been hampered by its complex biology. TNF signals through two receptors,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0d26b056e05d4cf01f61de56758d3f37

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.

Autor: Willoughby JE; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK., Dou L; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK., Bhattacharya S; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Jackson H; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Seestaller-Wehr L; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Kilian D; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Bover L; Immunology Department/ Genomics Medicine Department, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Voo KS; ORBIT, Institute of Applied Cancer Science, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Cox KL; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK., Murray T; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK., John M; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK., Shi H; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Bojczuk P; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Jing J; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Niederer H; Biopharm Discovery, GlaxoSmithKline Research & Development Limited, Stevenage, UK., Shepherd AJ; Protein, Cellular and Structural Sciences, GlaxoSmithKline Research & Development Limited, Gunnels Wood Road, Stevenage, UK., Hook L; Biopharm Discovery, GlaxoSmithKline Research & Development Limited, Stevenage, UK., Hopley S; Biopharm Discovery, GlaxoSmithKline Research & Development Limited, Stevenage, UK., Inzhelevskaya T; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK., Penfold CA; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK., Mockridge CI; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK., English V; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK., Brett SJ; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Srinivasan R; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Hopson C; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Smothers J; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Hoos A; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Paul E; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA.; GlaxoSmithKline, Durham, North Carolina, USA., Martin SL; Biopharm Discovery, GlaxoSmithKline Research & Development Limited, Stevenage, UK., Morley PJ; Immunology Research Unit, GlaxoSmithKline Research & Development Limited, Gunnels Wood Road, Stevenage, UK., Yanamandra N; Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania, USA msc@soton.ac.uk Niranjan.x.yanamandra@gsk.com., Cragg MS; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK msc@soton.ac.uk Niranjan.x.yanamandra@gsk.com.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jul 04; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 04.